A new HIV antiretroviral shows promise as a long-acting, oral prophylactic agent, according to a new study by Izzat Raheem, Tracy Diamond and colleagues from Merck & Co., Inc., Rahway, NJ, U.S., ...
Pre-exposure prophylaxis (PrEP) – taking antiretroviral drugs to protect people from acquiring HIV infection—is revolutionising the prevention of HIV around the world. However, a global study led by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results